Grzeskowiak Luke E, Qassim Alaa, Jeffries Bill, Grivell Rosalie M
SA Pharmacy, Flinders Medical Centre, SA Health, Adelaide, South Australia, Australia.
The Robinson Research Institute, School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia.
Intern Med J. 2017 Jul;47(7):747-753. doi: 10.1111/imj.13467.
Intravenous iron is commonly utilised in pregnancy when treatment with oral is not tolerated or where rapid replenishment of iron stores is required.
To examine the relationship between doses of intravenous iron administered during pregnancy according to different maternal bodyweight measures and subsequent treatment response.
Retrospective cohort study of pregnant women with confirmed iron deficiency anaemia who received intravenous iron polymaltose at a tertiary teaching hospital in Australia from 1 January 2014 to 31 January 2016. Diagnosis of anaemia and/or iron deficiency, infusion dosage characteristics and haematological parameters were collected from paper-based case notes and electronic records. The dose of intravenous iron administered was examined relative to maternal total bodyweight (TBW), ideal bodyweight (IBW) (equation = 45.5 kg + 0.9 kg/cm for each cm over 152 cm) and adjusted bodyweight (equation = IBW + [0.4 × (TBW - IBW)]).
A total of 122 pregnancies was identified where women had confirmed iron deficiency anaemia and received a single infusion of intravenous iron polymaltose. Dose-response relationships were evident between change in haemoglobin from treatment until delivery and intravenous iron dose according to adjusted bodyweight (adjusted beta coefficient 0.70 (95% CI 0.24-1.15)) and pre-pregnancy total bodyweight (adjusted beta coefficient 0.83 (95% CI 0.36-1.29)), but not ideal bodyweight (adjusted beta coefficient 0.37 (95% CI -0.04-0.78)). Calculating iron deficit using adjusted bodyweight most closely matched that based on a physiological estimate of iron deficit according to weight-based total blood volume.
Optimal treatment outcomes in pregnant women requiring intravenous iron may be reached by dosing according to adjusted pre-pregnancy bodyweight rather than ideal bodyweight.
当口服铁剂不耐受或需要快速补充铁储备时,孕期通常会使用静脉铁剂。
根据不同的母体体重测量方法,研究孕期静脉铁剂剂量与后续治疗反应之间的关系。
对2014年1月1日至2016年1月31日在澳大利亚一家三级教学医院接受静脉注射聚麦芽糖铁的确诊缺铁性贫血孕妇进行回顾性队列研究。从纸质病历和电子记录中收集贫血和/或缺铁的诊断、输注剂量特征和血液学参数。根据母体总体重(TBW)、理想体重(IBW)(公式=45.5kg+超过152cm每厘米0.9kg)和调整体重(公式=IBW+[0.4×(TBW-IBW)])来检查静脉注射铁剂的剂量。
共确定了122例孕妇,她们确诊缺铁性贫血并接受了单次静脉注射聚麦芽糖铁。从治疗到分娩期间血红蛋白的变化与根据调整体重(调整后的β系数为0.70(95%CI 0.24-1.15))和孕前总体重(调整后的β系数为0.83(95%CI 0.36-1.29))计算的静脉铁剂剂量之间存在明显的剂量反应关系,但与理想体重(调整后的β系数为0.37(95%CI -0.04-0.78))无关。使用调整体重计算铁缺乏量与基于根据体重计算的全血容量的铁缺乏生理估计值最为接近。
对于需要静脉铁剂治疗的孕妇,根据孕前调整体重而非理想体重给药可能会达到最佳治疗效果。